Effect of COMBinAtion therapy with remote ischemic conditioning and exenatide on the Myocardial Infarct size: a two-by-two factorial randomized trial (COMBAT-MI)
- 25 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Basic Research in Cardiology
- Vol. 116 (1), 1-12
- https://doi.org/10.1007/s00395-021-00842-2
Abstract
Remote ischemic conditioning (RIC) and the GLP-1 analog exenatide activate different cardioprotective pathways and may have additive effects on infarct size (IS). Here, we aimed to assess the efficacy of RIC as compared with sham procedure, and of exenatide, as compared with placebo, and the interaction between both, to reduce IS in humans. We designed a two-by-two factorial, randomized controlled, blinded, multicenter, clinical trial. Patients with ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention (PPCI) within 6 h of symptoms were randomized to RIC or sham procedure and exenatide or matching placebo. The primary outcome was IS measured by late gadolinium enhancement in cardiac magnetic resonance performed 3–7 days after PPCI. The secondary outcomes were myocardial salvage index, transmurality index, left ventricular ejection fraction and relative microvascular obstruction volume. A total of 378 patients were randomly allocated, and after applying exclusion criteria, 222 patients were available for analysis. There were no significant interactions between the two randomization factors on the primary or secondary outcomes. IS was similar between groups for the RIC (24 ± 11.8% in the RIC group vs 23.7 ± 10.9% in the sham group, P = 0.827) and the exenatide hypotheses (25.1 ± 11.5% in the exenatide group vs 22.5 ± 10.9% in the placebo group, P = 0.092). There were no effects with either RIC or exenatide on the secondary outcomes. Unexpected adverse events or side effects of RIC and exenatide were not observed. In conclusion, neither RIC nor exenatide, or its combination, were able to reduce IS in STEMI patients when administered as an adjunct to PPCI.Keywords
Funding Information
- Instituto de Salud Carlos III (PIE 13/00027)
- Departament de Salut, Generalitat de Catalunya (PERIS SLT/2381/2016)
This publication has 51 references indexed in Scilit:
- Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of IschemiaCirculation: Cardiovascular Interventions, 2012
- Peri-Infarct Zone on Early Contrast-Enhanced CMR Imaging in Patients With Acute Myocardial InfarctionJACC: Cardiovascular Imaging, 2011
- Cardioprotective Role of Remote Ischemic Periconditioning in Primary Percutaneous Coronary Intervention: Enhancement by Opioid ActionJACC: Cardiovascular Interventions, 2010
- Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat heartsThrombosis and Haemostasis, 2010
- Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion InjuryJournal of the American College of Cardiology, 2009
- Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heartRegulatory Peptides, 2008
- Myocardial Reperfusion InjuryThe New England Journal of Medicine, 2007
- Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat HeartsThe Journal of pharmacology and experimental therapeutics, 2006
- A fresh look at reperfusion injuryCardiovascular Research, 1998
- Tissue‐specific expression of the human receptor for glucagon‐like peptide‐I: brain, heart and pancreatic forms have the same deduced amino acid sequencesFEBS Letters, 1995